Forging a position as an innovative player in
infectious disease vaccines and therapies

Licensing Strategy and Available Licenses

BioDiem welcomes inquiries from potential partners on the licensing and collaboration opportunities available. BioDiem has world-class in-house expertise in the areas of vaccines and infectious disease therapy development. The Company also has an existing partnering network that spans the globe, which has provided access to top research facilities in the development of its asset portfolio.

Non-confidential summaries of each licensing opportunity are available upon request from the Company. Contact info@biodiem.com

The following technologies are available for licence or collaboration as detailed below:

Product/technology Indication Licenses Available
LAIV technology (intranasal influenza vaccine technology)
mammalian cell-based production
Influenza Global licence
excluding Russia and CIS.
LAIV technology (intranasalinfluenza vaccine technology) egg-based production method
Influenza  Developed world markets